QUINCE THERAPEUTICS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • December 18th, 2024 • Quince Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Quince Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC (each individually an “Agent” and together, the “Agents”), as follows:
QUINCE THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [], 20__ Debt SecuritiesIndenture • December 18th, 2024 • Quince Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
INDENTURE, dated as of [], 20__, among QUINCE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
